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160Gy to the PTV (GTV + 2mm) and Bard Quicklink system is 
used to implant I125 radioactive seeds. Multi-modal manual 
rigid and non-rigid transformations between MR and CT scans 
were performed on the first 9 patients with three software 
solutions: the treatment planning system Variseed, a 
research platform 3D Slicer and a commercial solution 
Mirada. MR onto CT registrations were approved by an expert 
uro-radiologist and quantitative evaluations of the 
registrations were performed by calculating the means of 
vectors displacement marked on four relevant points of 
interest detected on the I125 seeds. For the dosimetry, an 
assessment of the impact of these readjustments on the 
initial dose matrix was also performed in Mirada by applying 
the deformation to the initial contours and injecting the 
initial dose matrix. 
 
Results: For the first 9 patients, evaluation of registration 
gives means of vectors displacement of 1.52mm [0.36-2.6] 
with Variseed, 0.62mm [0.26-1.29] with 3D Slicer and 
0.42mm [0.24-0.81] with Mirada. Examples of fusions are 
illustrated in Figure1. Concerning the dosimetric data and 
considering the most relevant criteria from the initial 
outline, the D90%(Gy) to the prostate and respectively for 
the target has a mean difference of +0.68Gy and -12Gy. The 
D30%(Gy) and the D10%(Gy) to the urethra respectively have 
a mean difference of -0.99 and -5.58Gy. Lastly, D1cc(Gy) to 




Conclusion: Target volume definition remains a crucial step 
for focal brachytherapy as only confirmed tumor biopsy sub-
volumes of the prostate are treated. Registration procedures 
tested in our institute confirmed the need to implement 
precise rigid and non-rigid fusion of image to delineate 
relevant target volumes on different modalities. In addition, 
dosimetry evaluation on the registrations showed the impact 
of the deformations in high dose gradients. 
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Purpose or Objective: The High-dose-rate brachytherapy as 
monotherapy in one fraction, is a treatment option in 
patients with low-risk prostate cancer and can be used as an 
alternative to the low-dose-rate brachytherapy.Compared to 
the low-dose-rate, the HDR as monotherapy has not proven 
long-term results with regard to disease control. It is not 
known what dose of treatment should be used to increase the 
biochemical control, survival control disease and reduce 
unaffordable toxic effects. 
 
Material and Methods: Results on patients treated with high-
dose-rate brachytherapy as monotherapy are presented 
below. 
Sample: A series of 75 patients between 2008 and 2013 
treated with high-dose-rate brachytherapy (HDR) single dose 
of 19 Gy (62) and 20.5 Gy (13) were selected. 
A technique of guided-ultrasound brachytherapy and 
dynamic-calculated intraoperative dose was used. 
 
Results: The results show an overall survival of 91.3% of 
patients, with survival free of disease of 97% and a 
biochemical control of 72.5%. 
Patients toxicity: Acute urinary toxicity: 53.8% (grade 2). 
Chronic urinary toxicity: 49.2% (grade 2). Acute 
gastrointestinal toxicity: 86.2% (grade 1). Chronic 
gastrointestinal toxicity: 89% (grade 1).Acute urinary 
retention rate of 2.9%. 
 
Conclusion: HDR prostate brachytherapy as monotherapy in 
one single fraction of 19 Gy does not provided adequate 
biochemical control and survival free disease rates. It is 
necessary more studies to establish what would be the most 
appropiate dose to obtain higher rates of disease control 
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Purpose or Objective: Evaluate the relationship between 
RTOG G2-G3 urinary morbidity after prostate brachytherapy 
and urethral doses at the end of real-time dosimetry 
planning. 
 
Material and Methods: From November 2007 to December 
2010, 204 prostate cancer patients underwent monotherapy 
I-125 seeds brachytherapy in our institution. Real-time US 
guided dosimetry planning was performed with Variseed 7.0 
or 8.0. Of the 204 patients, 11 (5.4%) developed an acute 
urinary retention and required a urinary catheter from 2 
weeks to 7 months (G2 morbidity), and 7 patients (3.4%) 
required a transurethral resection of the prostate (G3 
morbidity).  
In a retrospective study, detailed urethral dosimetry was 
evaluated at the end of the real-time implant. Assessed 
values included maximum dose, V80, V100, V150 and D90 for 
both overall urethra and segmented urethra (as base, 
midgland and apex urethra). 1.5-mm and 2.5-mm urethral 
expansions were also reviewed for all dosimetry parameters. 
To check if dose homogeneity around urethral regions was 
related to morbidity, subtraction of expanded minus non-
expanded urethral dosimetry parameters was also performed. 
In total, 111 parameters were reviewed.  
T-Student test and U Mann-Whitney test were used to 
compare differences between patients free of urinary 
morbidity from those presenting G2 and G3 morbidity. p 
<0.05 was considered significant. 
 
Results: No correlation was found between non-expanded 
urethra doses and urinary morbidity. 
Best result (p=0.005) for distinguishing free-morbidity cohort 
from G2-G3 morbidity-cohort was obtained for subtraction of 
the maximum dose of the non-expanded minus 2.5-mm-
expanded overall urethra.  
